Retina Specialists of Idaho is proud to take part in clinical research trials for many common retinal conditions. We are committed to medical research and the advancement of treatments for retinal diseases. While many medical conditions do not have a “cure”, we strive to provide the latest technology and treatments available for retinal disorders and are actively involved in multiple clinical research trials in hopes of expanding our treatment options for patients. Below is a list of trials we are currently participating in. If you are interested in any of the trials below please contact our office and speak with our study coordinator, Alycia Harwood (208-938-5624)
Diabetic Macular Edema (DME)
Study Title: GLIMMER
A Phase III, two-year study for patients 18 years old or older with type I or II diabetes and treatment naïve DME. Their HbA1c must be 12% or less, vision between 20/25 and 20/320, and a central OCT thickness of 320 microns or more. Subjects enrolled in the study will be randomized to one of two groups. Group A will receive the study drug, KSI-301, per an individualized treatment regimen after three monthly loading doses. Group B will receive aflibercept (Eylea®) every eight weeks after five monthly loading doses. Sham injections will be performed when a treatment is not required to protect masking. Study duration is 2 years.
Non Proliferative Diabetic Retinopathy (NPDR)
Study Title: GLOW
A Phase III, two-year study for patients 18 years old or older with type I or II diabetes and treatment naïve Moderate or Severe NPDR. Their HbA1c must be 12% or less, vision 20/40 or better, and no DME (central OCT thickness less than 320 microns). Subjects enrolled in the study will be randomized to one of two groups. Group A will receive the study drug, KSI-301, per a specified treatment regimen. Group B will not be treated but to preserve masking will receive sham injections on the same specified intervals. Rescue treatments are available to group B if DME or neovascularization develops during the study.
Branch Retinal Vein Occlusion (BRVO)
Study Title: BEACON
A Phase III, one-year study for patients 18 years old or older with treatment naïve visual impairment secondary to BRVO. The subject’s vision must be between 20/25 and 20/320 with a central OCT thickness of 320 microns or greater. Subjects enrolled in the study will be randomized to one of two groups. Group A will receive the study drug, KSI-301, every eight weeks after two loading doses, followed by a six-month individualized treatment regimen. Group B will receive aflibercept monthly for 6 doses followed by a six-month individualized treatment regimen. Sham injections will be performed when a treatment is not required to protect masking. Study duration is 1 year.
Geographic Atrophy due to Age-Related Macular Degeneration (AMD)
Study Title: TELESCOPE
A genetic screening study for patients 55 years old or older with treatment-naïve visual impairment secondary to Geographic Atrophy due to AMD. Subjects enrolled in the study will be asked to provide a saliva sample to determine if the participant meets pre-specified genotype criteria. If criteria are met the subject may be able to enroll in an ongoing or future gene therapy intervention clinical trial. Patients who do not meet the initial pre-specified genotype criteria will be kept on a registry to be considered for future studies for which they may be eligible for participation. There is no cost to the patient for this genetic screening and patients will be reimbursed for reasonable travel costs incurred.
For more information or to refer a patient, please contact Study Coordinator Alycia Harwood at (208)-938-5624 or business@retinaidaho.com. For additional trial details, please refer to the study on ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04603937 (GLIMMER), https://clinicaltrials.gov/ct2/show/NCT04592419 (BEACON), https://clinicaltrials.gov/ct2/show/NCT05066230 (GLOW), or https://www.gyroscopetx.com/clinical-trials (TELESCOPE).